Clinical trials: Cutaneous Sarcoidosis
Cutaneous Sarcoidosis, Granuloma Annulare
Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.
- Trial name
- NCT03910543
- Testing
- Tofacitinib 5 mg twice daily
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University